PP
IOVA icon

PDT Partners’s Iovance Biotherapeutics IOVA Stock Holding History

PDT Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-216,880
Closed -$1.39M – 644
2022
Q4 		$1.39M Buy
216,880
+9,955
+5% +$77.7K 0.22% 154
2022
Q3 		$1.98M Buy
206,925
+191,276
+1,222% +$2.21M 0.3% 71
2022
Q2 		$173K Buy
+15,649
New +$205K 0.02% 842
2021
Q2 		– Sell
-17,030
Closed -$539K – 882
2021
Q1 		$539K Buy
+17,030
New +$706K 0.04% 493
2015
Q3 		– Sell
-68,814
Closed -$631K – 1409
2015
Q2 		$631K Buy
+68,814
New +$768K 0.02% 900

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PDT Partners's IOVA Position: Q1 2023 in Review

PDT Partners sold out of Iovance Biotherapeutics (IOVA) in Q1 2023, closing a stake of 216,880 shares — an estimated $1.39M sold.

PDT Partners first reported a position in IOVA in Q2 2015 and held it in 5 quarters. The position peaked at $1.98M in Q3 2022. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

  • PDT Partners reported no remaining Iovance Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • PDT Partners sold 216,880 Iovance Biotherapeutics shares in Q1 2023, an estimated $1.39M.
  • PDT Partners first reported a position in Iovance Biotherapeutics in Q2 2015 and held it in 5 quarters.
  • PDT Partners's Iovance Biotherapeutics position peaked at $1.98M in Q3 2022.
  • 228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.